Endo agrees to pay $8.8 million to settle Oklahoma opioid case

Endo Pharmaceuticals will pay about $8.8 million to settle claims by the state of Oklahoma that the company's marketing played a role in the opioid abuse crisis.

Endo Pharmaceuticals will pay about $8.8 million to settle claims by the state of Oklahoma that the company's marketing played a role in the opioid abuse crisis. Oklahoma Attorney General Mike Hunter's office said that most of the money will go into an Opioid Lawsuit Settlement Fund, which also contains the $85 million settlement with Teva Pharmaceutical Industries in June. Hunter has commended Endo for the steps it has taken to mitigate the opioid epidemic, saying that its executives have worked "to find a solution, not a cover-up, as we have discovered with numerous other companies during our years-long investigation." Without admitting liability or wrongdoing, Endo has agreed to suspend marketing for opioids in the state through branded and unbranded materials. The company has terminated all research and development of new opioid medications. In September, Endo agreed to pay $10 million to two Ohio counties to settle lawsuits related to claims about its branded and generic opioid medications.